Theraclone Completes First Dosing in Influenza A Drug Trial

The Phase I study will enrol up to 40 healthy adult volunteers to assess the safety profile of a single intravenous administration of TCN-032 compared to placebo.

Seattle-based biotechnology company Theraclone Sciences has completed its first patient dosing in a Phase I trial to investigate TCN-032 as a treatment for influenza A virus.

The randomised, double-blind, dose-escalation trial is supported in part by Theraclone's multi-year R&D agreement with Zenyaku Kogyo to identify conserved, essential antibody targets and develop candidates for the treatment of pandemic and severe seasonal influenza.

The Phase I study will enrol up to 40 healthy adult volunteers to assess the safety profile of a single intravenous administration of TCN-032 compared to placebo. The study will also provide pharmacokinetic and immunogenicity data.